Search results for " effect"

showing 10 items of 7524 documents

Ticlopidine in the Treatment of Multiple Atherosclerotic Arteriopathy: a Strain Gauge Plethysmography and Döppler Spectrum Analysis Evaluation

1987

The effect of ticlopidine was compared with flunarizine in patients with iliac–femoral and / or femoral–popliteal arteriosclerotic arteriopathy accompanied by lesions of the cervical arteries of no haemodynamic significance. In the lower limbs, plethysmography (strain gauge measurements) and Döppler ultrasonography integrated by spectral analysis of the cervical arteries showed qualitative and quantitative improvements of the regional haematic flow. Side-effects were negligible which suggests that ticlopidine is useful in the treatment of multiple arteriosclerotic arteriopathy.

medicine.medical_specialtyPathologyTiclopidineArteriosclerosisCervical ArteryHemodynamics030204 cardiovascular system & hematologyBiochemistry03 medical and health sciencessymbols.namesake0302 clinical medicineInternal medicineHumansMedicinePlethysmograph030212 general & internal medicineTiclopidineFlunarizineAgedUltrasonographybusiness.industryVascular diseaseBiochemistry (medical)Cell BiologyGeneral MedicineMiddle Agedmedicine.diseasePlethysmographyCardiologysymbolsbusinessDoppler effectBlood Flow VelocityFlunarizinemedicine.drugStrain gauge plethysmographyJournal of International Medical Research
researchProduct

The use of topical corticoids in oral pathology

2009

This review examines the most important aspects of the use of topical corticosteroids in oral pathology. We provide a detailed analysis of the most common types of corticosteroids used, their methods of application and the clinical data that must be managed in order to monitor the effectiveness of the treatment. We also analyze the correctable causes of treatment failure and the possible adverse effects that may occur after applying these drugs. All of this is achieved by conducting a critical review of these concepts.

medicine.medical_specialtyPathologybusiness.industryAdrenal cortex hormonesAdministration TopicalMouth Mucosamedicine.disease:CIENCIAS MÉDICAS [UNESCO]Treatment failureOtorhinolaryngologyAdrenal Cortex HormonesUNESCO::CIENCIAS MÉDICASOral and maxillofacial pathologyMedicineHumansSurgerybusinessAdverse effectIntensive care medicineMouth mucosaMouth DiseasesGeneral Dentistry
researchProduct

Adherence issues related to sublingual immunotherapy as perceived by allergists.

2010

Silvia Scurati1, Franco Frati1, Gianni Passalacqua2, Paola Puccinelli1, Cecile Hilaire1, Cristoforo Incorvaia3, Italian Study Group on SLIT Compliance 1Scientific and Medical Department, Stallergenes, Milan, Italy; 2Allergy and Respiratory Diseases, Department of Internal Medicine, Genoa; 3Allergy/Pulmonary Rehabilitation, ICP Hospital, Milan, ItalyObjectives: Sublingual immunotherapy (SLIT) is a viable alternative to subcutaneous immunotherapy to treat allergic rhinitis and asthma, and is widely used in clinical practice in many European countries. The clinical efficacy of SLIT has been established in a number of clinical trials and meta-analyses. However, because SLIT is self-administered…

medicine.medical_specialtyPathologygenetic structuresefficacyAlternative medicineMedicine (miscellaneous)Adherence Cost Efficacy Side effects Sublingual immunotherapySettore MED/10 - Malattie Dell'Apparato Respiratoriosublingual immunotherapyALLERGENcostmedicineSubcutaneous immunotherapySublingual immunotherapyadherenceClinical efficacyIntensive care medicinePharmacology Toxicology and Pharmaceutics (miscellaneous)sublingual immunoterapyOriginal ResearchAsthmaAEROALLERGENSadherence; sublingual immunotherapy; efficacy; cost; side effectsbusiness.industryHealth Policymedicine.diseaseSliteye diseasesClinical trialside effectsPatient Preference and Adherenceadherence; sublingual immunoterapy; efficacy; cost; side effects.immunotherapysense organsAllergistsADHERENCE TO TREATMENTbusinessSocial Sciences (miscellaneous)
researchProduct

Systematic review of the association between particulate matter exposure and autism spectrum disorders

2017

Particulate matter (PM) as an environmental pollutant is suspected to be associated with autism spectrum disorders. The aim of the present study was to review the epidemiological literature currently available on the relation between PM exposure and diagnosis of ASD. The PubMed database was searched from November 2015 up to January 2016 by one of the authors. We included observational studies (cohort and case control studies) published in English carried out in children within the last 10 years, measuring PM exposure and health outcomes related to ASD. 13 studies met the inclusion criteria. Four of the studies found no association between PM exposure and ASD. The other 8 studies show positi…

medicine.medical_specialtyPediatricsAutism Spectrum Disorder010501 environmental sciences01 natural sciencesBiochemistry03 medical and health sciences0302 clinical medicinePregnancyStatistical significanceEnvironmental healthEpidemiologymedicineHumansVehicle Emissions0105 earth and related environmental sciencesGeneral Environmental Sciencebusiness.industryPublic healthConfoundingmedicine.diseasePrenatal Exposure Delayed EffectsCohortAutismFemaleParticulate MatterObservational studybusiness030217 neurology & neurosurgeryCohort study
researchProduct

Chelation treatment in sickle-cell-anaemia: much ado about nothing?

2011

Summary Blood transfusions may prevent and treat serious complications related to sickle-cell disease (SCD) when performed according to specific guidelines. However, blood transfusion requirements in SCD inevitably lead to increased body iron burden. An adequate chelation treatment may prevent complications and reduce morbidity and mortality. This review evaluates the effectiveness, safety and costs of chelation treatment. The included trials were examined according to the recommendations of the American College of Cardiology (ACC) and the American Heart Association (AHA). Overall, 14 trials and a total of 502 patients with SCD were included in this review. Deferoxamine alone (s.c. or i.v.)…

medicine.medical_specialtyPediatricsBlood transfusionDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentAnemia Sickle CellDiseaseIron Chelating Agentslaw.inventionBody ironchemistry.chemical_compoundRandomized controlled triallawmedicineHumansChelationIntensive care medicinebusiness.industryDeferasiroxHematologyChelation TherapyDeferoxamineTreatment OutcomechemistryCosts and Cost AnalysisDeferipronebusinessChelation treatment sickle-cell-diseasemedicine.drug
researchProduct

Recent epidemiological studies on ionizing radiation and childhood cancer in Germany.

1998

The results from recent epidemiological studies based on the German Childhood Cancer Registry are summarized.An oecological study covers 16 years' incidence of childhood malignancies in areas surrounding nuclear facilities and in matched control regions. Two population-based case control studies explore potential risk factors of childhood leukaemia in the state of Lower Saxony (1988 93) and in all western states of Germany (1992-94).There was no increased incidence of childhood leukaemia and other malignancies in the vicinity of nuclear installations. X-ray examinations during pregnancy and in early childhood were not associated with an increased risk of childhood leukaemia. There were no d…

medicine.medical_specialtyPediatricsNeoplasms Radiation-InducedPopulationCohort StudiesPregnancyRisk FactorsGermanyRadiation IonizingEpidemiologyMedicineHumansRadiology Nuclear Medicine and imagingEarly childhoodRisk factoreducationChildLeukemia Radiation-InducedChildhood Cancer Registryeducation.field_of_studyPregnancyRadiological and Ultrasound Technologybusiness.industryIncidence (epidemiology)Case-control studyRadiobiologymedicine.diseaseRadiographyCase-Control StudiesChild PreschoolPrenatal Exposure Delayed EffectsFemalebusinessRadioactive Hazard ReleasePower PlantsInternational journal of radiation biology
researchProduct

The dilemma for patients with chronic hepatitis C: treat now or warehouse?

2013

Dual therapy with peginterferon and ribavirin, the only treatent for chronic hepatitis C available In Italy and in many other ountries worldwide up to 2013, obtains satisfactory response ates in infections with hepatitis C virus (HCV) genotype 2, but far rom optimal for other genotypes [1,2]. Eradication requires 6–12 onths of therapy, with significant inconvenience for patients: dverse reactions force premature termination in about 20% of atients and reduced the quality of life for almost all who persist n treatment. In view of the important and prolonged side effects, nterferon-based treatment is perceived as a nightmare by many symptomatic,well-being, socially activepatients (the largema…

medicine.medical_specialtyPediatricsTime FactorsProlineHepatitis C virusAlpha interferonmedicine.disease_causeAntiviral AgentsTelaprevirPolyethylene Glycolschemistry.chemical_compoundLiver diseaseBoceprevirDrug DiscoveryRibavirinmedicineHumansProtease InhibitorsAdverse effectWatchful WaitingDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaHepatitis C Chronicmedicine.diseaseSurgeryEastern europeanchemistryHCVDrug Therapy CombinationbusinessOligopeptidesmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy

2016

ABSTRACT Objective: To evaluate the cost-effectiveness of bedaquiline plus background drug regimens (BR) for multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) in Italy. Methods: A Markov model was adapted to the Italian setting to estimate the incremental cost-effectiveness ratio (ICER) of bedaquiline plus BR (BBR) versus BR in the treatment of MDR-TB and XDR-TB over 10 years, from both the National Health Service (NHS) and societal perspective. Cost-effectiveness was evaluated in terms of life-years gained (LYG). Clinical data were sourced from trials; resource consumption for compared treatments was modelled according to advice from an expert c…

medicine.medical_specialtyPediatricsTuberculosisCost effectivenessBedaquilinelcsh:Business03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSocietal perspectivemedicineOriginal Research Article030212 general & internal medicineResource consumptionSensitivity analysescost-effectivenessDisease treatmenthealth care economics and organizationsbusiness.industrylcsh:Public aspects of medicinelcsh:RA1-1270medicine.diseaseNational health serviceMDR tuberculosis030228 respiratory systemchemistryItalyEmergency medicineXDR tuberculosisOriginal ArticleBedaquilinebusinesslcsh:HF5001-6182Journal of Market Access & Health Policy
researchProduct

EPA-0666 – Long-term maintenance of efficacy of extended-release guanfacine hydrochloride (GXR) in children and adolescents with attention-deficit/hy…

2014

Introduction GXR, a selective α2A-adrenergic agonist, is a non-stimulant ADHD treatment approved in the USA for children and adolescents, and in Canada for children. Objectives To evaluate long-term maintenance of efficacy of GXR in children and adolescents with ADHD who respond to an initial open-label, short-term trial. Aims To determine if there is a higher rate of treatment failure for placebo vs GXR during the double-blind randomised-withdrawal phase (RWP) (NCT01081145). Methods Patients (6–17 years) meeting DSM-IV-TR criteria for ADHD, baseline ADHD Rating Scale-IV (ADHD-RS-IV) ≥32 and Clinical Global Impressions-Severity (CGI-S) ratings ≥4 were enrolled. Following 7-week dose optimiz…

medicine.medical_specialtyPediatricsbusiness.industryVital signsLong term maintenancemedicine.diseasePlaceboDouble blindPsychiatry and Mental healthmental disordersPhysical therapymedicineClinical endpointAttention deficit hyperactivity disorderGuanfacine HydrochlorideAdverse effectbusinessEuropean Psychiatry
researchProduct

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

2011

Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

medicine.medical_specialtyPediatricspml; iris; multiple sclerosis; natalizumabMultiple SclerosisNeurologypmlMEDLINEProgressive MultifocalDermatologyRelapsing-RemittingAntibodies Monoclonal HumanizedAntibodiesLeukoencephalopathyMultiple Sclerosis Relapsing-RemittingNatalizumabLeukoencephalopathyMonoclonalmedicineHumansAdverse effectAntibodies; Monoclonal; Humanized Antibodies; therapeutic use Humans Leukoencephalopathy; Progressive Multifocal; chemically induced Multiple Sclerosis; Relapsing-Remitting; drug therapyHumanizedMultiple sclerosis Natalizumab PML IRISirisbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisLeukoencephalopathy Progressive MultifocalAntibodies MonoclonalGeneral Medicinemedicine.diseasedrug therapyPsychiatry and Mental healththerapeutic usechemically inducednatalizumab multiple sclerosis treatment guidelinesPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusinessmedicine.drug
researchProduct